Can-Fite BioPharma Ltd. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 7 of 7 Posts
Week In Review: Shanghai Junshi Biosciences Files For $500 Million Hong Kong IPO
Article By: ChinaBio® Today Saturday, August 11, 2018 7:27 PM EDT
Shanghai Junshi Biosciences has filed for a Hong Kong IPO that is expected to raise up to $500 million. Junshi is developing a pipeline of 13 biologic drugs, including immuno-oncology treatments.
In this article: SGYP, CELG, GILD, CANF, BGNE
Read
Biotech Digest – JAZZ Reports Positive Results, CTSO Inks New Contract, AMGN Forges Collaboration
Article By: KKD Healthcare Analytics Tuesday, April 25, 2017 10:15 AM EDT
Capricor Therapeutics announced encouraging six-month results in a Phase 1/2 clinical trial. Jazz Pharmaceuticals reported results from its Phase 2/3 clinical trial. Amgen announced its new collaboration with Novartis.
In this article: NVS, EAPH, ACHN, JAZZ, AMGN, CANF, CAPR, CTSO
Read
Can-Fite Gearing-Up For Phase 2 NASH Program
Article By: Jason Napodano Wednesday, March 1, 2017 1:50 PM EDT
Can-Fite's entire market capitalization is only $33 million and I have to believe that the majority of that value is Phase 3 piclidenoson for the treatment of rheumatoid arthritis and psoriasis.
In this article: CANF
Read
CanFite's Piclidenoson Positioned For Successful Phase 3 In Psoriasis
Article By: Jason Napodano Wednesday, November 2, 2016 3:01 PM EDT
Can-Fite BioPharma Ltd. announced that the company reached an agreement with the European Medicines Agency on the final design of a global pivotal Phase 3 trial for its lead drug candidate, piclidenoson, in the treatment of psoriasis.
In this article: CANF
Read
Can-Fite An Emerging NASH Play With CF102
Article By: Jason Napodano Thursday, October 13, 2016 9:10 AM EDT
On October 13, 2016, Can-Fite Biopharma Ltd (CANF) announced it has submitted the clinical trial protocol for its Phase II study of CF102 in the treatment of NAFLD, the precursor to NASH, to a leading Institutional Review Board (IRB) in Israel.
In this article: CANF Also: AGN, GILD, ICPT
Read
E Can-Fite Biopharma Receives Fast Track Status For Liver Cancer Drug, Stock Almost Doubles
Article By: Terry Chrisomalis Thursday, September 17, 2015 10:46 PM EDT
Shares of Can-Fite Biopharma were up 95.24% today after announcing that the FDA has given a fast track designation for its liver cancer drug.
In this article: CANF
Read
Healthcare Review: CPRX, CANF, ACST, NWBO, ACT
Article By: BioMedReports Wednesday, October 1, 2014 3:35 AM EDT
The Dow Jones Industrial Average rose 37 points, or 0.2%, to 17108. The S&P 500 added four points, or 0.2%, to 1982, and the Nasdaq Composite Index rose six points, or 0.1%, to 4512.
In this article: NWBO, ACST, CPRX, ACT, CANF
Read
1 to 7 of 7 Posts